Amantadine for levodopa-induced dyskinesias: A 1-year follow-up study

Archives of Neurology

Volumn 56, Issue 11, 1999, Pages 1383-1386

  Metman, Leo Verhagen ^a   Del Dotto, Paolo ^a   LePoole, Kaatje ^a   Konitsiotis, Spiros ^a   Fang, John ^a   Chase, Thomas N ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; LEVODOPA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DYSKINESIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AMANTADINE; ANTIPARKINSON AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 0032706028     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.11.1383     Document Type: Article

References (13)

1. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol. 1996;69:497-501.
2. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport. 1994;5:2586-2583.
3. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol. 1996;39:574-578.
4. Blanchet BJ, Verhagen Metman L, Mouradian MM, Chase TN. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov Disord. 1996;11:580-581.
5. Verhagen Metman L, Del Dotto P, Natte R, van den Munckhof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology. 1998;51:203-206.
6. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-aminoadamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol. 1991;206:297-300.
7. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents: preclinical studies. Neurosci Biobehav Rev. 1997;21:455-468.
8. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 1998;50:1323-1326.
9. Schwab RS, Poskanzer DC, England ACJ, Young RR. Amantadine in Parkinson's disease: review of more than two years' experience. JAMA. 1972;222:792-795.
10. Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol. 1987; 10:522-526.
11. Parkes JD, Baxter RC, Curzon G, et al. Treatment of Parkinson's disease with amantadine and levodopa: a one-year study. Lancet. 1971;1:1083-1086.
12. Greulich W, Fenger E. Amantadine in Parkinson's disease: pro and contra. J Neural Transm Suppl. 1995;46:415-421.
13. Factor SA, Molho ES, Brown DL. Acute delirium after withdrawal of amantadine in Parkinson's disease. Neurology. 1998;50:1456-1458.